Skip to main content
Premium Trial:

Request an Annual Quote

Gregor Diagnostics Closes $900K Seed Financing Round

NEW YORK (360Dx) — Gregor Diagnostics announced today that it has raised $900,000 in seed funding, which the company will use to further develop its prostate cancer screening test.

The financing was led by First Round and Green Park & Golf Ventures. Other participants include the Wisconsin Alumni Research Foundation, Nat Turner and Zach Weinberg of Flatiron Health, existing investor Health Wildcatters.

The at-home test is designed to measure a combination of protein, methylated DNA, and prostate cancer microparticles in seminal fluid to detect prostate cancer, as well as differentiate between aggressive and indolent forms of the disease.

According to Gregor CEO Tobias Zutz, the seed financing will enable the company to evaluate the test in a trial of about 200 patient samples.

"We're really trying to tackle this problem from both angles by decreasing overdiagnosis and overtreatment while enabling more effective detection of aggressive prostate cancer, and this is an important first step toward that goal," he said in a statement.